Inclusion Criteria:

- Patients with newly diagnosed metastatic colorectal cancer who have started
first-line Xeloda-based chemotherapy in accordance with the current Hungarian label

Exclusion Criteria:

- History of serious or unexpected reaction to fluoropyrimidine therapy

- Hypersensitivity to the active ingredient of Xeloda or to any of the excipients of
the product, or to fluorouracil

- Known dihydropyrimidine dehydrogenase deficiency

- Pregnancy or lactation

- Inadequate bone marrow, hepatic or renal function

- Treatment with sorivudine or its chemical analogues (e.g. brivudine)

- If any contraindication for any drug used in the combination treatment schedules is
present, the drug in question cannot be used